title: Factor VIII levels and the risk of pre-eclampsia, HELLP syndrome, pregnancy related hypertension and severe intrauterine growth retardation.
abstract: OBJECTIVE
  Recently, acquired as well as genetic prothrombotic factors are associated with thrombotic events. These factors have also been related to conditions of uteroplacental insufficiency such as pre-eclampsia, HELLP syndrome and severe intrauterine growth restriction (IUGR). The aim of this study was to determine whether elevated factor VIII levels are associated with uteroplacental insufficiency, in particular pre-eclampsia, HELLP syndrome or pregnancy-induced hypertension and intrauterine growth retardation.
  
  
  METHODS
  Plasma samples of 75 women with a history of pregnancy complicated by pre-eclampsia, HELLP syndrome, pregnancy induced hypertension or intrauterine growth restriction were tested for factor VIII:C (FVIII:C) levels at a minimum of 10 weeks post-partum. Laboratory results were compared to factor VIII:C levels found in a healthy control group of 272 women.
  
  
  RESULTS
  Mean factor VIII:C levels were similar at 123 IU/dl in both the patient group and the controls. In a logistic regression model, after adjusting for age and blood group, no effect of factor VIII:C levels on the risk of pregnancy complications was observed, with the exception of IUGR with (OR 2.9, CI 1.0-8.7) or without hypertension (OR 2.0, CI 0.7-6.4).
  
  
  CONCLUSIONS
  If the elevated level of factor VIII would be the sole factor responsible for the increased risk observed, one would expect to find an effect of blood group on risk as well (blood group being an important determinant of FVIII:C). While no such effect could be shown a causal relationship between elevated levels of factor VIII and conditions of uteroplacental insufficiency such as pre-eclampsia, HELLP syndrome, pregnancy-induced hypertension and IUGR is not very likely.
authors.affiliation: Department of Obstetrics, Leiden University Medical Center, K6-27, PO Box 9600 2300 RC Leiden, The Netherlands.
authors.forename: C P J
authors.initials: CP
authors.lastname: Witsenburg
authors.forename: F R
authors.initials: FR
authors.lastname: Rosendaal
authors.forename: J M
authors.initials: JM
authors.lastname: Middeldorp
authors.forename: F J M
authors.initials: FJ
authors.lastname: Van der Meer
authors.forename: S A
authors.initials: SA
authors.lastname: Scherjon
mesh_terms: D000017:ABO Blood-Group System / Q000032:analysis; D005169:Factor VIII / Q000032:analysis*; D005260:Female; D005317:Fetal Growth Retardation / Q000097:blood*; D017359:HELLP Syndrome / Q000097:blood*; D006801:Humans; D006973:Hypertension / Q000097:blood*; D046110:Hypertension, Pregnancy-Induced / Q000097:blood*; D011225:Pre-Eclampsia / Q000097:blood*; D011237:Predictive Value of Tests; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood; D012044:Regression Analysis; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D000017:ABO Blood-Group System; D005169:Factor VIII